With Nigeria still accounting for nearly one-third of the global malaria burden, CHI Pharmaceuticals Limited, a member of the TGI Group, has intensified its campaign to combat the disease through community education, strategic partnerships, and access to trusted antimalarial treatments.
Speaking at a World Malaria Day event organized by the National Association of Patent and Proprietary Medicine Dealers (NAPPMED) in Lagos, CHI’s Chief Operating Officer, Mr. Shriram Iyer, described malaria as “a national emergency that demands relentless action.” He called for a united front to empower health workers and consumers with the tools to prevent and treat the disease effectively.
“Malaria continues to threaten the lives of millions, especially women and children. We are committed to partnering with frontline providers like PPMVs to deliver life-saving education and access to quality medicines,” Iyer said.
The event, themed “Malaria Ends With Us: Re-invent, Re-imagine and Re-ignite,” provided a platform for CHI Pharmaceuticals to spotlight its recently relaunched antimalarial, Co-Mal®, as a reliable solution in treating uncomplicated malaria. The company also addressed the escalating danger of counterfeit and substandard medications, reinforcing its commitment through its new nationwide campaign, “Co-Mal® On, Malaria Gone.”
CHI Pharmaceuticals pledged to deepen its collaboration with NAPPMED and further scale outreach programs to promote early diagnosis, prevention, and trusted treatment options at the grassroots level—where the malaria fight is most urgent.
